Wockhardt Ltd

- Wockhardt intends to seek external funding primarily for its ongoing clinical trial of WCK 5222, requiring about USD 30 million over the next 12 to 15 months. - The funding approach includes alternate sources such as debt funding and monetization of non-core assets. - No specific new equity fundraising is mentioned, but promoter commitment has increased significantly over recent years, with promoter loans converted into equity and additional funds raised via a rights issue in the past. - For CapEx, apart from clinical trials, there are no manufacturing-related CapEx requirements because manufacturing is outsourced to FDA-approved facilities. - Overall, they aim to fund R&D and clinical trials through a mix of cash flow, debt, and asset monetization without heavily relying on operating cash flow.

- Planned CapEx of approximately USD 30 million primarily to complete the clinical trial for WCK 5222 (Page 12, 7). - No manufacturing CapEx required for WCK 5222 as production is outsourced to FDA-approved European facilities (Page 12). - Restructuring of US business includes shutting down own manufacturing in Morton Grove, shifting to third-party manufacturing, resulting in savings of about USD 12 million annually (Page 3). - Ongoing strategic collaboration with Serum for vaccine manufacturing in the UK to drive growth (Page 6). - Investment focus on R&D, particularly biological and drug discovery, maintaining 8-9% of revenue for R&D with shifting priority from pharmaceutical to biological R&D (Page 9). - Exploring alternate funding sources including debt funding and asset monetization for clinical trial and R&D investments (Page 7).

- Diabetes portfolio (insulin, glargine) in emerging markets expected to drive large growth; current presence ~$50 million with a covered market of $1.5 billion. - Emerging markets including Latin America, Asia, Russia CIS, and growing MENA region showing improvement and growth. - UK business growing with increased market share and aggressive product filings (23 filed since 2020, 24 more in next two years). - Vaccine business with Serum collaboration expected to be a game changer, with reserved 150 million doses capacity and sustained increasing business and profitability. - Biologicals and biosimilars to grow faster than generics; biologics revenue expected to increase from 20% to 30% of total in next 2-3 years. - New product launches planned: 14 in India and 25 in UK during 2024-25, including insulin Aspart and other diabetes-related launches. - US sales maintained via third-party manufacturing, expecting ~40% gross margin with reduced losses. - Overall growth momentum positive and expected to accelerate in coming years.

- The US business restructuring is expected to cut losses by approximately USD 10 million, improving bottom-line profitability and aiming for about 40% overall margin in US operations. - The US business, previously a financial drain, is expected to turn profitable within two years. - Biologics and biosimilars currently contribute ~20% of revenue, projected to increase to ~30% in 2-3 years, driving faster growth. - The company targets positive PBT (Profit Before Tax) and cash EBITDA growth by FY24 and significant profitability improvements in FY25. - New product launches in India, UK, Latin America, MENA, and emerging markets will contribute to revenue growth. - Total clinical trial investment for WCK 5222 estimated at USD 30 million, funded by alternate sources without impacting cash flow. - Emphasis on R&D, new drug discovery, and vaccine collaborations (Serum deal) expected to bolster margins and growth. - Overall, management is positive on accelerating profitable growth and improved financial health over the next 2-3 years.

The transcript does not explicitly mention the current or expected order book or pending orders for Wockhardt Ltd. However, some relevant points indicating business prospects and volumes include: - Serum deal guarantees a certain minimum quantity of vaccine doses post-initial phase with expected high margin per dose. - Company aims to achieve vaccine production of 150 million doses per annum through collaboration with Serum. - Product launches planned: 14 in India and 25 in the UK during FY24-25. - Continuous filings and launches in emerging markets with focus on biologicals and biosimilars to grow from 20% to 30% revenue contribution in 2-3 years. - Clinical trials ongoing for WCK 5222 with global enrollment, intending completion in 15-18 months, supporting future product approvals. - Manufacturing in US and Canada shifted to third-party companies to improve margins and maintain sales volume. No direct numeric values on pending order backlog were disclosed.